CClinicalTrials.gg
Active, not recruitingNCT07048691Updated Jul 2, 2025

Prenatal and Postnatal Ultrasonographic Evaluation of Myelomeningocele to Predict Post-Surgical Outcomes

An observational study in Myelomeningocele, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 28 Weeks to 40 Weeks. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Superior University · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
20
Ages
28 Weeks to 40 Weeks
Sex
All
01

Study summary

Myelomeningocele (MMC), also known as open spina bifida, is a serious congenital condition in which the cord and meninges protrude through the spinal column's defective bony encasement due to a defective closure of the posterior portion of the neural tube between the fourth week of pregnancy.

Read the detailed description

The formation of the defect is influenced by both genetic and environmental factors, while the exact cause is yet unknown. There is currently no effective treatment for this common and debilitating central nervous system (CNS) dysfunction.

02

Conditions studied

  • Myelomeningocele

Browse trials for

03

In context

Meningomyelocele

56 studies on the registry are indexed under Meningomyelocele; 14 are open to participants now.

This study's enrollment of 20 is below the median of 30 across 17 observational studies indexed under Meningomyelocele.

Browse Meningomyelocele studies →

Lead sponsor

Superior University is the lead sponsor of 242 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 40 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

After approval from the institutional ethical committee, a total number of patients presenting to the Radiology and Peads Neurosurgery department of Allied Hospital, Faisalabad, that met the inclusion criteria was selected. After obtaining informed consent from each patient and attendant of the patient, transabdominal ultrasound was examined longitudinal, transverse and oblique plans, ultrasound with a high- resolution convex probe was used by the radiologist.

Inclusion criteria

  • Gestational age 3rd trimester, Lesion between T1 and S1, Hindbrain herniation and Normal karyotype

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation pregnancy
  • Other fetal anomalies unrelated to myelomeningocele
  • History of incompetent cervix, Other serious maternal medical conditions
  • Inability to adhere to travel and follow-up requirements
  • Contraindication to surgery and Inability to meet trial psychosocial criteria.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • G.E HEALTHCARE ultrasound machine with high-resolution convex probe

    Diagnostic Test: G.E HEALTHCARE ultrasound machine with high-resolution convex probe

Interventions

  • Diagnostic testG.E HEALTHCARE ultrasound machine with high-resolution convex probe

    After approval from the institutional ethical committee, a total number of patients presenting to the Radiology and Peads Neurosurgery department of Allied Hospital, Faisalabad, that met the inclusion criteria was selected. After obtaining informed consent from each patient and attendant of the patient, transabdominal ultrasound was examined longitudinal, transverse and oblique plans, ultrasound with a high- resolution convex probe was used by the radiologist

06

What researchers measure

Primary outcomes

  1. self administered questioner

    self administered questioner for yelomeningocele patients scroing range fron 0-40. 0 is for lower and 40 is worse and higher

    Time frame: 12 Months

07

Study locations

1 site
  • Allied Hospital
    Faisalābad, Punjab Province, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048691
Lead sponsor
Superior University
Responsible party
Muhammad Naveed Babur (Principal Investigator, Superior University) — Principal investigator
First posted
Jul 2, 2025
Start date
Mar 17, 2025
Primary completion
Sep 1, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Jul 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion